文献速递乳腺癌泌尿男性生殖肿瘤

使用多基因风险评分预测男性BRCA1和BRCA2突变携带者的乳腺癌与前列腺癌风险

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
PubMed 文献 · J Clin Oncol · 2017-04-27

研究对1802名男性BRCA1/2突变携带者进行基因分型,构建基于88个女性乳腺癌易感变异和103个前列腺癌易感变异的加权多基因风险评分(PRS)。结果显示PRS与乳腺癌风险(每标准差OR 1.36)和前列腺癌风险(每标准差OR 1.56)相关,且在PRS分布极端处绝对风险差异大。结论认为PRS可能为男性携带者提供风险分层信息。

要点

  • 在男性BRCA1/2突变携带者中,基于88个女性乳腺癌易感变异的PRS与乳腺癌风险相关(每SD OR 1.36)。
  • 基于103个前列腺癌易感变异的PRS与前列腺癌风险相关(每SD OR 1.56)。
  • PRS极端百分位间绝对风险差异大,如BRCA2携带者80岁时前列腺癌风险5th vs 95th百分位为19% vs 61%。

核心结论

  • PRS可能为男性BRCA1/2突变携带者提供有信息的癌症风险分层,或有助于这些男性及其医生就乳腺癌和前列腺癌风险管理的类型和时机做出知情决策。

研究设计与样本

  • 研究对来自BRCA1/2修饰因子研究者联盟(CIMBA)的1802名男性BRCA1/2突变携带者使用定制Illumina OncoArray进行基因分型。
  • 使用已发表的效应估计值作为权重,构建加权多基因风险评分(PRS),研究已建立的乳腺癌和前列腺癌易感变异对男性BRCA1/2突变携带者癌症风险的联合效应。

主要发现

  • 在男性BRCA1/2突变携带者中,基于88个女性乳腺癌易感变异的PRS与乳腺癌风险相关(每标准差OR 1.36;95%CI 1.19至1.56;P=8.6×10^-6)。
  • 基于103个前列腺癌易感变异的PRS与前列腺癌风险相关(每标准差OR 1.56;95%CI 1.35至1.81;P=3.2×10^-9)。
  • 在PRS分布极端处观察到绝对癌症风险的大差异;例如,80岁时前列腺癌风险在PRS第5和第95百分位,BRCA1突变携带者从7%到26%,BRCA2突变携带者从19%到61%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated-for the first time to our knowledge-associations of common genetic variants with breast and prostate cancer risks for male carriers of BRCA1/ 2 mutations and implications for cancer risk prediction. Materials and Methods We genotyped 1,802 male carriers of BRCA1/2 mutations from the Consortium of Investigators of Modifiers of BRCA1/2 by using the custom Illumina OncoArray. We investigated the combined effects of established breast and prostate cancer susceptibility variants on cancer risks for male carriers of BRCA1/2 mutations by constructing weighted polygenic risk scores (PRSs) using published effect estimates as weights. Results In male carriers of BRCA1/2 mutations, PRS that was based on 88 female breast cancer susceptibility variants was associated with breast cancer risk (odds ratio per standard deviation of PRS, 1.36; 95% CI, 1.19 to 1.56; P = 8.6 × 10-6). Similarly, PRS that was based on 103 prostate cancer susceptibility variants was associated with prostate cancer risk (odds ratio per SD of PRS, 1.56; 95% CI, 1.35 to 1.81; P = 3.2 × 10-9). Large differences in absolute cancer risks were observed at the extremes of the PRS distribution. For example, prostate cancer risk by age 80 years at the 5th and 95th percentiles of the PRS varies from 7% to 26% for carriers of BRCA1 mutations and from 19% to 61% for carriers of BRCA2 mutations, respectively. Conclusion PRSs may provide informative cancer risk stratification for male carriers of BRCA1/2 mutations that might enable these men and their physicians to make informed decisions on the type and timing of breast and prostate cancer risk management.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lecarpentier J, Silvestri V, Kuchenbaecker KB, et al. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017. PMID: 28448241. doi:10.1200/JCO.2016.69.4935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。